Editorial

Is ramucirumab still the only second-line treatment in metastatic gastric cancer?

Khalil El Gharib

https://orcid.org/0000-0003-2006-8232

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Search for more papers by this author

Hampig Raphael Kourie

*Author for correspondence:

E-mail Address: hampig.kourie@hotmail.com

https://orcid.org/0000-0002-2502-5402

Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Search for more papers by this author

Published Online:8 Oct 2020https://doi.org/10.2217/pgs-2020-0118

View article

Keywords:

References

1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz. Gastroenterol. 14(1), 26–38 (2019).Medline, CAS, Google Scholar
2. Bendell J, Yoon HH. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer. (2020). https://ezproxy.usj.edu.lb:4555/contents/initial-systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer?search=gastric%20cancer&source=search_result&selectedTitle=9∼150&usage_type=default&display_rank=9Google Scholar
3. Fanotto V, Fornaro L, Bordonaro R et al. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: a multicentre real-world study. J. Geriatr. Oncol. 10(4), 591–597 (2019).Crossref, Medline, Google Scholar
4. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v38–49 (2016).Crossref, Medline, CAS, Google Scholar
5. Ghosn M, Tabchi S, Kourie HR, Tehfe M. Metastatic gastric cancer treatment: second-line and beyond. World J. Gastroenterol. 22(11), 3069 (2016).Crossref, Medline, CAS, Google Scholar
6. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 10(9), 903–912 (2009).Crossref, Medline, Google Scholar
7. Pericay C, Rivera F, Gomez-Martin C, Nuñez I, Cassinello A, Imedio ER. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med. 5(12), 3464–3474 (2016).Crossref, Medline, Google Scholar
8. Murahashi S, Takahari D, Wakatsuki T et al. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int. J. Clin. Oncol. 23(1), 92–97 (2018).Crossref, Medline, CAS, Google Scholar
9. Kang B, Kwon O-K, Chung H, Yu W, Kim J. Taxanes in the treatment of advanced gastric cancer. Molecules 21(5), 651 (2016).Crossref, Google Scholar
10. Lorenzen S, Thuss-Patience PC, Pauligk C et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: interim safety and efficacy results from the Phase II RAMIRIS study (AIO-STO-0415) of the German Gastric Group at AIO. J. Clin. Oncol. 37(Suppl. 15), 4023–4023 (2019).Google Scholar
11. Chung HC, Arkenau H-T, Lee J et al. Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase Ib results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7(1), 30 (2019).Crossref, Medline, Google Scholar
12. Alsina M, Moehler M, Hierro C, Guardeño R, Tabernero J. Immunotherapy for gastric cancer: a focus on immune checkpoints. Target Oncol. 11(4), 469–477 (2016).Crossref, Medline, Google Scholar
13. Kang Y-K, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 390(10111), 2461–2471 (2017).Crossref, Medline, CAS, Google Scholar
14. Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase II clinical KEYNOTE-059 trial. JAMA Oncol. 4(5), e180013–e180013 (2018).Crossref, Medline, Google Scholar
15. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 12(3), 354 (2006).Crossref, Medline, Google Scholar
16. Shitara K, Özgüroğlu M, Bang YJ et al. KEYNOTE-061: Phase III study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. Ann. Oncol. 29, v123 (2018).Crossref, Google Scholar
17. Hironaka S, Kadowaki S, Izawa N et al. A Phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. J. Clin. Oncol. 38(Suppl. 4), 352–352 (2020).Crossref, Google Scholar
18. Bang Y-J, Golan T, Lin C-C et al. Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small-cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). J. Clin. Oncol. (37(15), 2528–2528 (2020). Google Scholar
19. Koemans WJ, Chalabi M, van Sandick JW, van Dieren JM, Kodach LL. Beyond the PD-L1 horizon: in search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. Cancer Lett. 442, 279–286 (2019).Crossref, Medline, CAS, Google Scholar
20. Valentini A, Di Pinto F, Coletta S, Guerra V, Armentano R, Caruso M. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncol. Lett (18(2), 1775–1785 (2019). Medline, CAS, Google Scholar
21. Lee V, Murphy A, Le DT, Diaz LA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 21(10), 1200–1211 (2016).Crossref, Medline, CAS, Google Scholar
22. Vrána D, Matzenauer M, Neoral Č et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int. J. Mol. Sci. 20(1), 13 (2018).Crossref, Medline, Google Scholar
23. Giampieri R, Maccaroni E, Mandolesi A et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer 20(1), 156–163 (2017).Crossref, Medline, CAS, Google Scholar
24. Dolcetti R, De Re V, Canzonieri V. Immunotherapy for gastric cancer: time for a personalized approach? Int. J. Mol. Sci. 19(6), 1602 (2018).Crossref, Google Scholar
25. Chao J, Fuchs CS, Shitara K et al. Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy. J. Clin. Oncol. 38(Suppl. 4), 430–430 (2020).Crossref, Google Scholar
26. Fashoyin-Aje L, Donoghue M, Chen H et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24(1), 103–109 (2019).Crossref, Medline, CAS, Google Scholar
27. Zaanan A, Taieb J. How to better select patients with advanced gastric cancer for immunotherapy. Transl. Gastroenterol. Hepatol. 4, 6–6 (2019).Crossref, Medline, Google Scholar
28. Kwak Y, Seo AN, Lee HE, Lee HS. Tumor immune response and immunotherapy in gastric cancer. J. Pathol. Transl. Med. 54(1), 20–33 (2020).Crossref, Medline, Google Scholar
29. Bang Y-J, Cutsem EV, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).Crossref, Medline, CAS, Google Scholar
30. Li Q, Jiang H, Li H et al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget 7(31), 50656–50665 (2016).Crossref, Medline, Google Scholar
31. Bang Y-J. A randomized, open-label, Phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: tytan study. J. Clin. Oncol. 31(Suppl. 4), 11–11 (2013).Crossref, Medline, Google Scholar
32. Nishikawa K, Takahashi T, Takaishi H et al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102): advanced or recurrent gastric cancer (JFMC45-1102). Int. J. Cancer 140(1), 188–196 (2017).Crossref, Medline, CAS, Google Scholar
33. Bendell J, Yoon HH. Progressive, locally advanced unresectable, and metastatic esophageal and gastric cancer: approach to later lines of systemic therapy. (2020). https://ezproxy.usj.edu.lb:4555/contents/progressive-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer-approach-to-later-lines-of-systemic-therapy?search=gastric%20cancer&source=search_result&selectedTitle=3∼150&usage_type=default&display_rank=3#H81501608Google Scholar
34. Astor L. FDA approves frontline pembrolizumab for MSI-H/dMMR CRC. (2020). https://www.targetedonc.com/view/fda-approves-frontline-pembrolizumab-for-msi-h-dmmr-crcGoogle Scholar

Vol. 21, No. 17

Metrics

Downloaded 99 times

History

Received 21 August 2020

Accepted 17 September 2020

Published online 8 October 2020

Published in print November 2020

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download